Abstract
Preliminary study of three new sulfonamides as intestinal chemotherapeutic agents is reported : 2-sulfanilamido-5-carbamylthiazole, 2-(N4-succinamylsulfanilamido)-thiazole, and 2-(N4-succinylsulfanilamido)- 1 , 3, 4-thiadiazole.
The presence of the carbamyl group in the 5-position of sulfathiazole greatly reduces absorption from the gastro-intestinal tract and activity in vitro. However, marked anti-coli action was demonstrated in mice and dogs. Sulfacarbamylthiazole is relatively stable and activity is apparently due to the drug per se.
Replacement of the carboxy group of succinylsulfathiazole with the carbamyl group yields a compound considerably more labile than the parent drug. While absorption was slight following oral administration of succinamylsulfathiazole to mice and dogs, the drug showed but little anti-coli activity in vivo.
Substitution of the succinyl radical in the N4-position of sulfathiadiazole resuits in a compound highly active in the intestinal tract of both mice and dogs and only slightly absorbed into the blood. The anti-coli activity of succinylsulfathiadiazole was found to be much greater than that of sulfathalidine in mice and about equal to the latter drug in dogs. Data seem to establish succinylsulfathiadiazole as a potentially useful drug for trial in therapy of enteric infections.
Footnotes
- Received October 6, 1947.
- 1948 by The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|